Get the Stockscreener App
54.79
1.29%
0.3647
Pulse Biosciences Inc stock is traded at $54.79, with a volume of 51,560.
It is up +1.29% in the last 24 hours and up +24.17% over the past month.
Pulse Biosciences Inc is a novel bioelectric medicine company committed to health innovation using its patented Nano-Pulse Stimulation technology, a revolutionary energy modality that delivers nanosecond-duration pulses of electrical energy, each less than a millionth of a second long, to non-thermally clear targeted cells while sparing adjacent noncellular tissue. NPS technology, also referred to as Nanosecond Pulsed Field Ablation (nsPFA) technology delivers nanosecond pulses of electrical energy to nonthermally clear cells while sparing adjacent noncellular tissue.
See More
Previous Close:
$54.43
Open:
$54.5
24h Volume:
51,560
Relative Volume:
0.12
Market Cap:
$3.91B
Revenue:
$751.00K
Net Income/Loss:
$-74.57M
P/E Ratio:
-49.67
EPS:
-1.1031
Net Cash Flow:
$-55.52M
1W Performance:
+3.55%
1M Performance:
+24.17%
6M Performance:
+175.51%
1Y Performance:
+265.10%
1-Day Range:
$54.48
$56.61
1-Week Range:
$47.70
$58.90
52-Week Range:
$12.56
$58.90
Pulse Biosciences Inc Stock (PLSE) Company Profile
Name
Pulse Biosciences Inc
Sector
Industry
Phone
510-906-4600
Address
3957 POINT EDEN WAY, HAYWARD, CA
Compare PLSE vs ISRG, BDX, ALC, RMD, MDLN
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PLSE
Pulse Biosciences Inc
|
54.81 | 3.88B | 751.00K | -74.57M | -55.52M | -1.1031 |
ISRG
Intuitive Surgical Inc
|
367.33 | 127.34B | 11.03B | 3.16B | 3.22B | 8.7251 |
BDX
Becton Dickinson Co
|
176.31 | 48.05B | 21.37B | 1.41B | 3.07B | 3.9437 |
ALC
Alcon Inc
|
66.28 | 32.17B | 10.63B | 819.00M | 1.59B | 1.6577 |
RMD
Resmed Inc
|
217.38 | 31.67B | 5.54B | 1.52B | 1.74B | 10.37 |
MDLN
Medline Inc
|
31.99 | 28.42B | 29.14B | 1.07B | 1.05B | 1.1956 |
Pulse Biosciences Inc Stock (PLSE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-30-26 | Initiated | Mizuho | Outperform |
| Jul-07-25 | Initiated | Oppenheimer | Outperform |
| Jul-27-21 | Initiated | Stephens | Overweight |
| Mar-11-21 | Initiated | Maxim Group | Buy |
| Jan-26-21 | Reiterated | H.C. Wainwright | Buy |
| May-12-20 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Feb-14-20 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Feb-25-19 | Initiated | H.C. Wainwright | Buy |
View All
Pulse Biosciences Inc Stock (PLSE) Latest News
Why is Pulse Biosciences stock surging today? By Investing.com - Investing.com India
Freedom Capital initiates Pulse Biosciences stock with buy rating By Investing.com - Investing.com Australia
Why Pulse Biosciences Stock Popped Today - The Globe and Mail
Freedom Capital Markets Initiates Pulse Biosciences(PLSE.US) With Buy Rating, Announces Target Price $73 - Moomoo
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
Pulse Biosciences stock hits all-time high at 56.15 USD By Investing.com - Investing.com India
Pulse Biosciences stock hits all-time high at 56.15 USD - Investing.com
$Pulse Biosciences (PLSE.US)$ the squeeze is onnnnnnnn - Moomoo
PLSE Initiates Coverage by Freedom Capital Markets -- Price Targ - GuruFocus
Freedom Capital initiates Pulse Biosciences stock with buy rating - Investing.com
(PLSE) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Pulse Biosciences Stock Price Forecast. Should You Buy PLSE? - StockInvest.us
Pulse Biosciences stock holds steady as investors eye recent clinical and financial progress - AD HOC NEWS
Pulse Biosciences (PLSE) Grants Equity Awards to New Hires Amid High Price-to-Sales Valuation - GuruFocus
Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Pulse Biosciences Inc (DE) (PLSE) Financials – Balance Sheet, Profit & Loss, Cash Flow - Value Research
Pulse Biosciences COO Liane Teplitsky buys $99,971 in stock By Investing.com - Investing.com Australia
Pulse Biosciences COO Liane Teplitsky buys $99,971 in stock - Investing.com India
COO pays nearly $50 a share for Pulse Biosciences (NASDAQ: PLSE) - Stock Titan
Pulse Biosciences Inc (DE) (PLSE) Peer Comparison – Compare with Others - Value Research
$Pulse Biosciences (PLSE.US)$ New ATH 🔥 - Moomoo
Pulse Biosciences Reports Teplitsky Liane Rae as New Insider COO - Kalkine Media
Pulse Biosciences stock hits new high as insider buying fuels rally - ad-hoc-news.de
Pulse Biosciences stock hits all-time high at 51.0 USD - Investing.com
Pulse Biosciences stock hits all-time high at 51.0 USD By Investing.com - Investing.com Canada
Pulse Biosciences (PLSE) Slips 2% as Shares Approach Key Support at $45.19IV Crush Alert - vinanet.vn
Pulse Biosciences COO Liane Teplitsky buys $99,965 in stock By Investing.com - Investing.com Nigeria
PLSE | Pulse Biosciences, Inc Common FinancialsIncome Statement - Quiver Quantitative
Pulse Biosciences (NASDAQ: PLSE) links CFO options to value and revenue goals - Stock Titan
Pulse Biosciences Inc (DE) (PLSE) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
Pulse Biosciences COO Liane Teplitsky buys $99,965 in stock - Investing.com
Pulse Biosciences (PLSE), Why Is Attention Building Around It? - Sahm
Total assets of Pulse Biosciences, Inc. – HAM:6L8 - TradingView
Operating cash flow per share of Pulse Biosciences, Inc. – HAM:6L8 - TradingView
Free cash flow per share of Pulse Biosciences, Inc. – HAM:6L8 - TradingView
Pulse Biosciences stock hits all-time high at 48.92 USD - Investing.com
$Pulse Biosciences (PLSE.US)$ shorties getting squeezed - Moomoo
Pulse (PLSE) Results Review: EPS Clears the Reported Estimate; Trading Move: Shares Rise 2.22% in the Latest ReadingDividend Growth Analysis - Vinanet
Bank of America Corp DE Grows Stake in Pulse Biosciences, Inc $PLSE - MarketBeat
Pulse Biosciences (PLSE) Launched A $75 Million Offering, Is The Upside Already Priced In? - Sahm
Pulse Biosciences (NASDAQ:PLSE) Sets New 1-Year HighHere's Why - MarketBeat
Pulse (PLSE) Earnings Review: EPS Exceeds Its Estimate in the Current Update; Reaction Snapshot - vinanet.vn
This Onto Innovation Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - Sahm
This Okta Analyst Turns Bullish; Here Are Top 3 Upgrades For Monday - Benzinga
Pulse Biosciences, Inc (NASDAQ:PLSE) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Needham & Company LLC Initiates Coverage on Pulse Biosciences (NASDAQ:PLSE) - MarketBeat
PLSE Initiates Coverage On by Needham -- Price Target Announced at $58.00 - GuruFocus
Needham initiates Pulse Biosciences stock with buy on ablation tech By Investing.com - Investing.com Canada
Needham Initiates Pulse Biosciences at Buy With $58 Price Target - marketscreener.com
Pulse Biosciences (PLSE) Is Up 5.0% After Wider Losses And $75M ATM Plan Filed – Has The Bull Case Changed? - simplywall.st
PULSE BIOSCIENCES INC : NEEDHAM INITIATES COVERAGE WITH BUY RATING; TARGET PRICE $58 - Bitget
Pulse Biosciences Inc Stock (PLSE) Financials Data
Revenue
Net Income
Cash Flow
EPS
Pulse Biosciences Inc Stock (PLSE) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Teplitsky Liane Rae | Chief Operating Officer |
Aug 31 '26 |
Buy |
48.80 |
1,024 |
49,971 |
3,094 |
| Teplitsky Liane Rae | Chief Operating Officer |
Aug 28 '26 |
Buy |
48.35 |
1,034 |
49,994 |
2,070 |
| Teplitsky Liane Rae | Chief Operating Officer |
Aug 26 '26 |
Buy |
48.23 |
1,036 |
49,971 |
1,036 |
| LAVIOLETTE PAUL A | Chief Executive Officer |
May 11 '26 |
Buy |
19.69 |
15,000 |
295,350 |
15,000 |
| DUGGAN ROBERT W | Director |
May 11 '26 |
Buy |
19.69 |
660,233 |
12,999,988 |
48,211,433 |
| Danahy Kevin Patrick | Chief Commercial Officer |
Feb 18 '26 |
Option Exercise |
1.53 |
5,000 |
7,650 |
48,298 |
| Danahy Kevin Patrick | Chief Commercial Officer |
Feb 18 '26 |
Sale |
23.64 |
5,000 |
118,200 |
43,298 |
| Danahy Kevin Patrick | Chief Commercial Officer |
Feb 12 '26 |
Option Exercise |
1.53 |
20,000 |
30,600 |
63,298 |
| Danahy Kevin Patrick | Chief Commercial Officer |
Feb 13 '26 |
Option Exercise |
1.53 |
20,000 |
30,600 |
63,298 |
| Danahy Kevin Patrick | Chief Commercial Officer |
Feb 17 '26 |
Option Exercise |
1.53 |
20,000 |
30,600 |
63,298 |
0.21%
0.71%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):